US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019

On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event in Malmö. The presentation will be held at Clarion Hotel & Congress Malmö Live and Ascelia Pharma will start its presentation at 6pm CET.The presentation can also be followed live via: https://www.redeye.se/live/inv-aw-malmo-12-9 Program and registration for the event can be found here: https://www.redeye.se/events#/event/583611 For more information, please contact:Mikael Widell, IR & Communications ManagerEmail: mw@ascelia.comTel: +46 703 11

Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019

On 10th of September, Ascelia Pharma's CEO Magnus Corfitzen will present the latest development in the company at Operaterassen in Stockholm. The Share Day event (Aktiedagen) is organised by Swedish Shareholders' Association and Ascelia Pharma will start the presentation at 8.30am CET.The presentation can be followed live via: www.aktiespararna.se/tv/live  Program and registration for the day can be found here: https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-4 For more information, please contact:Mikael Widell, IR & Communications

Phase III study of Mangoral to start in H2-2019

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its full-year report for the period July 2018 - June 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q4 (APRIL-JUNE 2019) · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · Supportive feedback from EMA on the Phase III program for Mangoral · New patent application filed for Mangoral with potential to extend IP rights to year 2040 · IPO overallotment utilised raising SEK 22 million FINANCIAL SUMMARY IN Q4 (

Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019

Ascelia Pharma’s full-year report for the period July 2018 – June 2019 (FY 2018/2019) will be published on Thursday 22 August 2019 at 09:00 CET. A presentation for analysts, media and investors will be held the same day at 09:00 CET.The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos and CMO Carl Bjartmar. The presentation will be held in English.  The presentation can be followed live via the link:https://tv.streamfabriken.com/ascelia-pharma-q4-2018-2019  It will also be possible to take part of the audiocast afterwards at the same address or at

Fully financed Phase III program for Mangoral through the IPO

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its interim report for the period January-March 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/IMPORTANT EVENTS IN THE PERIOD · IPO of SEK 200 million · More than 6,000 new shareholders in the IPO – both institutional and private · Fully financed Phase III program for Mangoral IMPORTANT EVENTS AFTER THE PERIOD · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · IPO overallotment utilised raising SEK 22 million ·

Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the company has completed constructive discussions with the European Medicines Agency (EMA) regarding the clinical development program for Mangoral® as a contrast agent in patients with focal liver lesions and severe renal impairment. Ascelia Pharma will now finalise preparations for the clinical Phase 3 study and expects to enrol the first patient during the second half of 2019.Mangoral is an oral contrast agent for liver MRI developed to facilitate the visualisation of focal liver lesions, including liver metastases, using

Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow

Nasdaq Stockholm AB has today decided to admit the shares of Ascelia Pharma AB ("Ascelia Pharma" or the “Company") for trading on Nasdaq Stockholm with first day of trading tomorrow, Wednesday 13 March 2019. The shares will be traded under the ticker ACE and ISIN SE0010573113.The offering in Ascelia Pharma AB in connection with the listing on Nasdaq Stockholm was, as previously communicated, significantly oversubscribed. The offering provided Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the offering. The listing on Nasdaq Stockholm gives

Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The offering in Ascelia Pharma AB ("Ascelia Pharma" or the “Company") in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.

Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Ascelia Pharma AB ("Ascelia Pharma" or the “Company") has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the "Offering"). The Company's Board of Directors also intend to apply for admission to trading of the Company's shares on Nasdaq Stockholm

Ascelia Pharma receives positive feedback from FDA on design of the pivotal Phase 3 study with Mangoral®

Ascelia Pharma AB today announced that the company has successfully concluded discussions with the US Food and Drug Administration (FDA) regarding the study design for the single pivotal Phase 3 trial for Mangoral® as a contrast agent in patients with focal liver lesions and severe renal impairment.  Ascelia Pharma will now complete the preparatory work to start the trial and expects to enroll the first patient during the second half of 2019.Mangoral® is an oral contrast agent for liver MRI developed to facilitate the visualization of focal liver lesions, including liver metastases, using

Encouraging results from clinical Phase I study of Oncoral presented in a new publication

In continuation of the previously published poster presentation at ESMO in Munich, 19-23 October 2018, Ascelia Pharma has announced the encouraging Phase I results in a new publication titled Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.The publication, which is available on pubmed.gov , contains data from a dose escalation study in adult patients with solid tumors to assess safety, tolerability and pharmacokinetics of Oncoral,

Oncoral demonstrates encouraging results in clinical phase I

Ascelia Pharma has presented results of the Phase I study for Oncoral at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.The poster presentation contains data from a dose escalating study in adult patients with solid tumors to assess safety, tolerability and pharmacokinetics of Oncoral, an oral irinotecan formulation, given as single agent. An abstract (# 433P) for the presentation is published online via the EMSO website . The data demonstrated that Oncoral was well tolerated;

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media